Mark Nestor, MD, PhD
STP705 met the primary efficacy endpoint in an ongoing phase II study of patients with cutaneous squamous cell carcinoma in situ
(isSCC), according to topline results reported by Sirnaomics Inc., the developer of the small interfering RNA (siRNA) therapeutic.
STP705 has been granted FDA Orphan Drug Designations for the treatment of patients with cholangiocarcinoma, primary sclerosing cholangitis, and hepatocellular carcinoma. The designation is intended to expedite the review and development of treatments for rare diseases, defined as those affecting fewer than 200,000 people in the United States.
Sirnaomics Announces Positive Topline Results from Interim Analysis of Ongoing Phase II Clinical Trial Evaluating STP705 in Cutaneous Squamous Cell Carcinoma in situ (isSCC). Published April 9, 2020. https://bit.ly/2Vjbv8f. Accessed April 9, 2020.
... to read the full story